Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma

JAMA Surgery

Volumn 150, Issue 8, 2015, Pages 701-710

  Paniccia, Alessandro ^a   Hosokawa, Patrick ^a   Henderson, William ^a   Schulick, Richard D ^a   Edil, Barish H ^a   McCarter, Martin D ^a   Gajdos, Csaba ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVOR; COHORT ANALYSIS; COMMUNITY HOSPITAL; DYING; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PUERTO RICO; RETROSPECTIVE STUDY; UNITED STATES; CARCINOMA, PANCREATIC DUCTAL; MIDDLE AGED; NOMOGRAM; PANCREATIC NEOPLASMS; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL; SURVIVOR;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; UNITED STATES;

EID: 84939803723     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2015.0668     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1): 11-30.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378 (9791):607-620.
3. Dusch N, Weiss C, Ströbel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18(4): 674-681.
4. Nathan H, Wolfgang CL, Edil BH, et al. Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol. 2009;99(2):87-92.
5. Katz MHG, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836-847.
6. Ferrone CR, Brennan MF, Gönen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12(4): 701-706.
7. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247(3):456-462.
8. Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008;37(4):352-357.
9. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg. 1995;221(1):59-66.
10. The National Cancer Database (NCDB) http://ncdbpuf.facs.org. Accessed March 20, 2014.
11. Fritz A, Percy C, Jack A, Sobin LH, Parkin MD. International Classification of Diseases for Oncology, 3rd Revision. Geneva, Switzerland: World Health Organization; 2000.
12. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141(5):610-618.
13. Arias E. United States life tables, 2009. Natl Vital Stat Rep. 2014;62(7):1-63.
14. Czaja AS, Hosokawa PW, Henderson WG. Unscheduled readmissions to the PICU: epidemiology, risk factors, and variation among centers. Pediatr Crit Care Med. 2013;14(6): 571-579.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
16. Valsangkar NP, Bush DM, Michaelson JS, et al. N0/N1, PNL, or LNR? the effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17(2):257-266.
17. Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg. 2015; 261(5):961-969.
18. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008; 15(1):165-174.
19. Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372-377.
20. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237(1):74-85.
21. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277.
22. Seyedin S, Luu C, Stabile BE, Lee B. Effect of socioeconomic status on surgery for pancreatic adenocarcinoma. Am Surg. 2012;78(10): 1128-1131.
23. Murphy MM, Simons JP, Hill JS, et al. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer. 2009;115(17):3979-3990.
24. Abraham A, Al-Refaie WB, Parsons HM, Dudeja V, Vickers SM, Habermann EB. Disparities in pancreas cancer care. Ann Surg Oncol. 2013;20(6): 2078-2087.